Early prostaglandin E₁ treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

ABSTRACT:

Background

Central retinal artery occlusion (CRAO) is a vision-threatening emergency with no established effective treatment. Prostaglandin E₁ (PGE₁), known for its vasodilatory and cytoprotective properties, may offer therapeutic benefits for retinal ischemia.

Methods

In this retrospective study, we compared visual outcomes between CRAO patients who received intravenous PGE₁ within 24 hours of symptom onset (followed by oral administration) and those who received conventional therapy. PGE₁ was administered intravenously for 5 days.

Results

At one month, the PGE₁ group showed significantly better best-corrected visual acuity compared to the control group. Baseline structural retinal parameters, including maximal r

SUBMITTER: Sano H 

PROVIDER: S-EPMC12404978 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature